PDCD1 and esophageal squamous cell carcinoma: In the setting of locally advanced resectable thoracic ESCC, the combination of PD-1(L1) antibodies with chemotherapy or chemoradiotherapy as neoadjuvant therapy was under investigation in some phase II studies, most of which adopted chemotherapy plus immunotherapy as neoadjuvant therapy.